Catabasis: Negative Mid-stage Clinical Trial Results For DMD Drug

(RTTNews) - Shares of Catabasis Pharmaceuticals Inc. (CATB) shares plunged 70 percent on Wednesday after the drug maker said its mid-stage clinical trial for Edasalonexent, a Duchenne muscular dystrophy drug, failed to meet main endpoint.

The MoveDMD trial of edasalonexent for the treatment of Duchenne muscular dystrophy had thirty-one boys enrolled.

Catabasis said that patients in the trial who received the drug did not see any significant changes in lower leg muscle inflammation compared to those on placebo after 12 weeks. A higher dose of the drug resulted in improvements across multiple measures, but none of the changes were statistically significant, the company said.

"Although we did not meet the MRI T2 composite end point, the continued safety, tolerability and plasma exposure data in Part B of the MoveDMD trial are reassuring," said Jill C. Milne, Chief Executive Officer of Catabasis.